Piper Sandler upgraded Edwards Lifesciences (EW) to Overweight from Neutral with a price target of $80, up from $73. The firm sees a “better pathway” back to double-digit growth in fiscal 2026 for the company, given a “healthier” transcatheter aortic valve replacement business and the transcatheter mitral and tricuspid therapies ramp. Piper also likes Edwards’ positioning in an uncertain macro environment, citing a manageable tariff impact, non-deferrable procedures, and no capex exposure.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences Reports Strong Q1 Growth
- Edwards Lifesciences: Hold Rating Amid Strong Q1 Results and Future Challenges
- Closing Bell Movers: Robert Half down 15% after earnings miss
- Edwards Lifesciences reaffirms FY25 adjusted EPS $2.40-$2.50, consensus $2.45
- Edwards Lifesciences reports Q1 EPS 61c, consensus 60c
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue